NCT06331845View on ClinicalTrials.gov

Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2028

Conditions
Metastatic Nasopharyngeal CarcinomaIntermittent Systematic Chemotherapy
Interventions
DRUG

Gemcitabine

1000 mg/m2 on Days 1 and 8

DRUG

Cisplatin

a total of 80-100 mg/m2 for d1-3

DRUG

Paclitaxel protein-bound

260 mg/m2 on Day 1

DRUG

Capecitabine

a dose of 1-1.25 g/m2 twice daily in in 2 weeks for one cycle

DRUG

Tislelizumab

200 mg on Day 1

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV